PMID- 8528743
OWN - NLM
STAT- MEDLINE
DCOM- 19960201
LR  - 20191101
IS  - 0946-2716 (Print)
IS  - 0946-2716 (Linking)
VI  - 73
IP  - 8
DP  - 1995 Aug
TI  - Tumor-associated lymphocytes (TAL) are competent to produce higher levels of 
      cytokines in neoplastic pleural and peritoneal effusions than those found in sera 
      and are able to release into culture higher levels of IL-2 and IL-6 than those 
      released by PBMC.
PG  - 409-16
AB  - This work was designed to study the proliferative response of tumor-associated 
      lymphocytes (TAL) from neoplastic effusions against autologous tumor cells and 
      the immunophenotype pattern of TAL from neoplastic effusions and that of PBMC of 
      the same patients. We also compared the serum levels of the cytokines interleukin 
      (IL) 1 beta, 2 and 6, tumor necrosis factor-alpha (TNF alpha) and soluble IL-2 
      receptor (sIL-2R) with those present in neoplastic effusions of the same 
      patients. Moreover, we examined the ability of TAL and peripheral blood 
      mononuclear cells (PBMC) to produce and release the cytokines and sIL-2R and to 
      express membrane CD25 following their stimulation with phytohemagglutinin (PHA) 
      in vitro. Finally, we compared the cytokines/sIL-2R production and membrane CD25 
      expression by PHA-stimulated PBMC of the patients with neoplastic effusions with 
      a series of 90 cancer patients without neoplastic effusions and 20 normal healthy 
      subjects. Thirteen neoplastic pleural and eight peritoneal effusions were 
      collected from 11 patients with primary lung cancer, 7 with primary epithelial 
      ovarian cancer, 1 with breast cancer, 1 with pleural mesothelioma, and 1 with 
      pancreatic cancer. The proliferative response of TAL from neoplastic effusions 
      against autologous tumor cells was lower than the response to PHA, IL-2, and 
      anti-CD3, but significant. The percentage distribution of CD3+ and CD8+ 
      lymphocyte subpopulations was higher in peritoneal than in pleural effusions, 
      while the CD16+ subset was higher in pleural than in peritoneal effusions. The 
      percentage distribution of CD16+ was significantly lower in pleural effusions 
      than in PBMC of patients with pleural effusions.(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - Mantovani, G
AU  - Mantovani G
AD  - Department of Medical Oncology, University of Cagliari, Italy.
FAU - Maccio, A
AU  - Maccio A
FAU - Versace, R
AU  - Versace R
FAU - Pisano, M
AU  - Pisano M
FAU - Lai, P
AU  - Lai P
FAU - Esu, S
AU  - Esu S
FAU - Ghiani, M
AU  - Ghiani M
FAU - Dessi, D
AU  - Dessi D
FAU - Turnu, E
AU  - Turnu E
FAU - Santona, M C
AU  - Santona MC
AU  - et al.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - J Mol Med (Berl)
JT  - Journal of molecular medicine (Berlin, Germany)
JID - 9504370
RN  - 0 (Interleukin-2)
RN  - 0 (Interleukin-6)
SB  - IM
MH  - Aged
MH  - Ascitic Fluid/*immunology
MH  - Cell Division
MH  - Humans
MH  - Immunophenotyping
MH  - Interleukin-2/*blood
MH  - Interleukin-6/*blood
MH  - Leukocytes, Mononuclear/*immunology
MH  - Lymphocytes, Tumor-Infiltrating/*immunology/pathology
MH  - Middle Aged
MH  - Pleural Effusion, Malignant/*immunology
MH  - Tumor Cells, Cultured
EDAT- 1995/08/01 00:00
MHDA- 1995/08/01 00:01
CRDT- 1995/08/01 00:00
PHST- 1995/08/01 00:00 [pubmed]
PHST- 1995/08/01 00:01 [medline]
PHST- 1995/08/01 00:00 [entrez]
AID - 10.1007/BF00240140 [doi]
PST - ppublish
SO  - J Mol Med (Berl). 1995 Aug;73(8):409-16. doi: 10.1007/BF00240140.